Download video

FDA Regulation of Artificial Intelligence

1K views

Medmarc

3 weeks ago

FDA Regulation of Artificial Intelligence

FDA Regulation of Artificial Intelligence

FDA Advancing Generic Drugs 2025: Potential Pitfalls in Nitrosamine Risk Assessment and Control
26:13
FDA Advancing Generic Drugs 2025: Potential Pitfalls in Nitrosamine Risk Assessment and Control
by The FDA Learning Cache
REdI 2024 | D1S06 - Responsive Regulation of Artificial Intelligence in Drug Development
38:59
REdI 2024 | D1S06 - Responsive Regulation of Artificial Intelligence in Drug Development
by U.S. Food and Drug Administration
FDA Advancing Generic Drugs 2025: Comparative Physicochemical Characterization of Iron Products
19:46
FDA Advancing Generic Drugs 2025: Comparative Physicochemical Characterization of Iron Products
by The FDA Learning Cache
REdI 2024 | D2S05 - Artificial Intelligence\/Machine Learning: The New Frontier of Drug Development..
42:05
REdI 2024 | D2S05 - Artificial Intelligence\/Machine Learning: The New Frontier of Drug Development..
by U.S. Food and Drug Administration
Overview of Mild Cognitive Impairment and Different Dementias
57:59
Overview of Mild Cognitive Impairment and Different Dementias
by Emory Brain Health Community Outreach
Quality Considerations for Aseptic Processing
48:56
Quality Considerations for Aseptic Processing
by Pharmatech Associates, a USP company
FDA Regulatory Affairs Webinar - Asphalion
2:20:19
FDA Regulatory Affairs Webinar - Asphalion
by Asphalion
REdI 2024 | D2S02-1 - Improving Informed Consent
26:33
REdI 2024 | D2S02-1 - Improving Informed Consent
by U.S. Food and Drug Administration
GDF 2024 | D2S14 - Improving the Sterility Assurance Application to the FDA
17:49
GDF 2024 | D2S14 - Improving the Sterility Assurance Application to the FDA
by U.S. Food and Drug Administration
FDA Drug Safety Podcast: FDA identifies no harmful effects to date with brain retention of gadoli...
3:01
FDA Drug Safety Podcast: FDA identifies no harmful effects to date with brain retention of gadoli...
by U.S. Food and Drug Administration
FDA Advancing Generic Drug Development 2025: Session 4: Q\&A Panel and Day Two Closing
39:13
FDA Advancing Generic Drug Development 2025: Session 4: Q\&A Panel and Day Two Closing
by The FDA Learning Cache
FDA Advancing Generic Drug Development 2025: Compositional Sameness for Complex Polymeric Excipients
20:05
FDA Advancing Generic Drug Development 2025: Compositional Sameness for Complex Polymeric Excipients
by The FDA Learning Cache
FDA Advancing Generic Drugs 2025: Pharm\/Tox for the Safety Evaluation of Nitrosamine Impurities
20:55
FDA Advancing Generic Drugs 2025: Pharm\/Tox for the Safety Evaluation of Nitrosamine Impurities
by The FDA Learning Cache
GDF 2024 | D2S03-2 - Comparative Analyses Update
12:19
GDF 2024 | D2S03-2 - Comparative Analyses Update
by U.S. Food and Drug Administration
FDA Advancing Generic Drug Development 2025: Session 2: Q\&A Panel and Day 1 Closing
37:41
FDA Advancing Generic Drug Development 2025: Session 2: Q\&A Panel and Day 1 Closing
by The FDA Learning Cache
AI's FDA Embrace: Speeding Up Drug Approvals?
6:40
AI's FDA Embrace: Speeding Up Drug Approvals?
by Heartbeat: Salesforce \& AI for CIOs
AGDD 2024 | D2S10-2 - Analysis of ANDA Approval and Major Deficiencies A Case Study with Topical...
11:56
AGDD 2024 | D2S10-2 - Analysis of ANDA Approval and Major Deficiencies A Case Study with Topical...
by U.S. Food and Drug Administration
GDF 2024 | D2S06 - Nitrosamine Risk Assessment in Type II DMFs Supporting GDUFA Applications
21:09
GDF 2024 | D2S06 - Nitrosamine Risk Assessment in Type II DMFs Supporting GDUFA Applications
by U.S. Food and Drug Administration
AGDD 2024 | D2S05-1-Totality of Evidence Including Physiologically Based Pharmacokinetic Modeling...
11:53
AGDD 2024 | D2S05-1-Totality of Evidence Including Physiologically Based Pharmacokinetic Modeling...
by U.S. Food and Drug Administration